Steroid induced central serous retinopathy following follicular unit extraction in androgenic alopecia
Abstract
Dermatologists for various conditions and procedures commonly use corticosteroids worldwide. The development of central serous retinopathy is a lesser known complication occurring in <10% of the cases with steroid use. This case report highlights the development of central serous retinopathy after prescribing low dose of prednisolone 20 mg per day for androgenic alopecia during post-surgical follicular unit extraction (FUE) surgery follow-up that recovered spontaneously after gradual withdrawal of steroids. Therefore, awareness is required for its early detection and management as it has a potential of causing irreversible visual impairment.
Keywords
Full Text:
PDFReferences
Hardwig PW, Silva AO, Pulido JS. Forgotten exogenous corticosteroid as a cause of central serous chorioretinopathy. Clin Ophthalmol. 2008;2:199-201.
Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol. 2010;22:166-73.
Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR. Central serous chorioretinopathy in African-Americans. J Natl Med Assoc. 2003;95(7):553-9.
Guyer DR, Gragoudas ES, Spaide RF. Central serous chorioretinopathy. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology, 2nd ed. Philadelphia: WB Saunders Company; 2000:3:1974-1982.
Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN Elliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmolgy. 1997;104:1653-60.
Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging. 2004;35(2):165-7.
Acar U, Kucuk B, Agin A, Koc M, Sobaci G. Case report of tadalafil-induced central serous chorioretinopathy. J Clin Exp Ophthalmol. 2014;5:357.
Cotticelli L, Borrelli M, D'Alessio AC, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy and Helicobacter pylori. Euro J Opthalmol. 2006;16(2):274-8.
Moon SJ, Meiler WF. Retinal complications of bone marrow and solid organ transplantation. Curr Opin Ophthalmol. 2003;14(6):433-42.
Kian-Ersi F, Taheri S, Akhlaghi MR. Ocular disorders in renal transplant patients. Saudi J Kidney Dis. Transpl. 2008;19(5):751-5.
Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye Lond. 2010;24:1743-56.
Jenkins CD, Zyzanski SJ, Rosenman RH. Progress toward validation of computer-scored test for the type A coronary-prone behavior pattern. Psychosomatic Medicine. 1971;33:193-202.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psycho. 1959;32:50-5.
Clinical global impression. ECDEU assessment manual for psychopharamacology. Guy W, ed, Rockville, MD: US Department of Health, Education and Welfare, DHEW Publication No. (ADM); 1976:76-338.
Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN Elliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmolgy. 1997;104:1653-60.
Mondal LK, Sarkar K, Datta H, Chatterjee PR. Acute bilateral central serous chorioretinopathy following intra-articular injection of corticosteroids. Indian J Ophthamol. 2005;53:132-4.
Karadimus P, Kapitanjos A, Bouzas EA. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders. Arch Ophthalmol. 2004;122:784-6.
Zamir E. Central serous chorioretinopathy associated with adrenocorticotrophic hormone therapy. A case report and hypothesis. Arch Clin Exp Ophthalmol. 1997;235:339-44.
Wakakura M, Song E, Ishikawa S. Corticosteroid-induced central serous chorioretinopathy. Jpn J Opthalmol. 1997;41:180-5.
Caccavale A, Romanazzi F, Imparto M, Neagri A, Marro A, Ferentini F. Low dose aspirin as treatment of central serous chorioretinopathy. Clin Ophthmol. 2014;4:899-903.
Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor-1 in central serous chorioretinopathy. Am J Ophthmol. 1999;127(4):477-8.
WHO-UMC org. The uppsala monitoring centre. Available from: http://www.who-umc.org/. Accessed 19 February 2016.
Schumock GT, Thomton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.
American academy of ophthalmology. Basic and clinical sciences course. Retina and vitreous USA. San Francisco. 2008-2009;4:55-9.
Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752-63.
Lim JW, Ryu SJ, Shin MJ. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol. 2010;24(3):155-8.
Golshahi A, Klingmuller D, Holtz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol. 2010;88(5):576-81.